![](https://monteverdelaw.com/wp-content/uploads/case-logo/logicbio-therapeutics-inc.png)
LogicBio Therapeutics, Inc. (LOGC), relating to its proposed acquisition by AstraZeneca Rare Disease. Under the terms of the tender offer, LOGC shareholders will receive $2.07 in cash per share they own.
LogicBio Therapeutics, Inc. (LOGC), relating to its proposed acquisition by AstraZeneca Rare Disease. Under the terms of the tender offer, LOGC shareholders will receive $2.07 in cash per share they own.